
    
      Phase II, single arm, not randomized, European multicentric study designed to explore the
      activity of TSR-042, a human monoclonal anti-PD-1 inhibitor, in a population of patients with
      a diagnosis of advanced/metastatic clear cell sarcoma (CCS).
    
  